ICON plc (NASDAQ: ICLR), a global clinical research organization, has announced the schedule for its second-quarter 2026 financial results. The company plans to release its Q2 results after the U.S. stock market closes on Wednesday, July 29, 2026.
The announcement was disclosed in a Form 6-K filing, giving investors a confirmed timeline for the company’s next major financial update. The upcoming results will provide insight into ICON’s performance during the second quarter and offer investors a closer look at demand across the clinical research and healthcare services market.
Earnings Call Scheduled for July 30
Following the financial release, ICON will host a conference call and webcast on Thursday, July 30, 2026, at 8:00 a.m. Eastern Time. Management is expected to discuss the company’s quarterly performance, operating trends, financial results and broader business outlook during the call.
Investors and analysts will also have the opportunity to listen to management commentary that could provide additional context beyond the headline financial figures. A replay of the call is expected to become available approximately one hour after the conclusion of the live event.
Investors Focus on Growth and Profitability
The Q2 update comes as investors continue to assess ICON’s growth trajectory and profitability. In its first-quarter 2026 results, the company reported revenue of approximately $2.03 billion, while adjusted earnings per share stood at $2.50. ICON also reaffirmed its full-year 2026 guidance, projecting revenue between $7.85 billion and $8.15 billion and adjusted diluted earnings per share between $10.00 and $11.00.
The second-quarter results will therefore be closely watched for signs of whether the company is progressing in line with its annual targets. Investors may pay particular attention to revenue growth, margins, new business activity, backlog development and management’s outlook for the remainder of the year.
What Comes Next
ICON’s earnings announcement will provide a fresh assessment of the company’s operating momentum in a competitive clinical research market. The July 30 conference call could be especially important for investors seeking additional clarity on the company’s financial performance and expectations for the second half of 2026.
With the results scheduled for release after market close on July 29, market participants will have the opportunity to evaluate the numbers before hearing directly from management the following morning.
